Serious Candida Infections: Scynexis's Oral Antifungal Could Challenge Fluconazole

 
• By John Davis

Positive top-line results from the Phase IIb DOVE study of Scynexis's SCY-078, and progress with a new intravenous formulation, suggest the US biotech's new triterpenoid could be the first of a new class of antifungal agents for serious infections.  

Dove
SCY-078's results in the DOVE study were positive • Source: Shutterstock

More from Clinical Trials

More from R&D